{
    "2019-07-12": [
        [
            {
                "time": "",
                "original_text": "英百年旅游集团奄奄一息 复星料获旅游业务多数股权",
                "features": {
                    "keywords": [
                        "复星",
                        "旅游集团",
                        "股权"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "旅游"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星医药子公司赴港分拆上市获证监会核准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "子公司",
                        "上市",
                        "证监会"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "复星医药(02196.HK)：复宏汉霖拟发行境外上市外资股获证监会核准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "复宏汉霖",
                        "境外上市",
                        "证监会"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "帕金森病新药！第三代强效COMT抑制剂在美国申请上市，复星医药$1800万引入国内开发",
                "features": {
                    "keywords": [
                        "帕金森病",
                        "新药",
                        "复星医药",
                        "美国",
                        "国内开发"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "投资者审慎 港股缩量回稳",
                "features": {
                    "keywords": [
                        "投资者",
                        "港股",
                        "缩量",
                        "回稳"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}